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Abstract: miR-28-5p is downregulated in some tumor tissues in which it has been demonstrated to
have tumor suppressor (TS) activity. Here, we demonstrate that miR-28-5p acts as a TS in prostate
cancer (PCa) cells affecting cell proliferation/survival, as well as migration and invasion. Using
the miRNA pull out assay and next generation sequencing, we collected the complete repertoire of
miR-28-5p targets, obtaining a data set (miR-28-5p targetome) of 191 mRNAs. Filtering the targetome
with TargetScan 7, PITA and RNA22, we found that 61% of the transcripts had miR-28-5p binding
sites. To assign a functional value to the captured transcripts, we grouped the miR-28-5p targets into
gene families with annotated function and showed that six transcripts belong to the transcription
factor category. Among them we selected SREBF2, a gene with an important role in PCa. We validated
miR-28-5p/SREBF2 interaction, demonstrating that SREBF2 inhibition affects almost all the tumor
processes altered by miR-28-5p re-expression, suggesting that SREBF2 is an important mediator of
miR-28-5p TS activity. Our findings support the identification of the targetome of cancer-related
miRNAs as a tool to discover genes and pathways fundamental for tumor development, and potential
new targets for anti-tumor therapy.
Keywords: prostate cancer; miRNA targetome; SREBF2; miR-28-5p; miRNA pull out assay; microRNA
1. Introduction
miR-28-5p is a miRNA with a tumor suppressor (TS) activity downregulated in several tumor
tissues [1–6]. Increasing evidences indicate that miR-28-5p inhibited some well-characterized
oncogenes such as CCND1, HOXB3 [4] in colorectal carcinoma and IL-34 [7] and IGF-1 [1] in
hepatocellular carcinoma.
It has been demonstrated in vitro that miR-28-5p exerts its tumor suppressor activity by affecting
several aspects of tumor cell biology. miR-28-5p re-expression inhibited cell proliferation in B-cell
lymphomas and renal cell carcinoma regulating BAG1 [3] and RAP1B [2] expression, respectively.
Moreover, miR-28-5p inhibited cell migration and invasion in gastric cancer by repressing the AKT
Cells 2020, 9, 354; doi:10.3390/cells9020354 www.mdpi.com/journal/cells
Cells 2020, 9, 354 2 of 15
phosphorylation levels [6]. Interestingly, miR-28-5p, by regulating the triose-phosphate isomerase
(TPI) in colorectal carcinoma, contributed to the increased glycolytic capacity of the tumor cells [8].
Recently, two reports indicate that the capability of miR-28-5p to inhibit its targets is also regulated by
the sponge effect of long non-coding RNAs, such as UCA1 [5] and CCAT1 [9]. Although some reports
about the molecular targets through which the miR-28-5p exerts its TS activity in different tumor types
are available, most experimental studies validate only one or a few miRNA targets at once. However,
a single miRNA simultaneously interacts and regulates hundreds of mRNA molecules, generating a
complex regulatory network.
Previously, we demonstrated, for the first time, that miR-28-5p is downregulated in two prostate
cancer (PCa) cell lines, and that it acts as a TS in PCa cells [10]. Here we explored the complete
repertoire of the miR-28-5p targets in a PCa cell line. We chose to use an experimental rather than a
computational approach to reduce false positives. Several high-throughput experimental methods are
now available, most of which are based on the sequencing (NGS) of RNA isolated by the crosslinking
and immunoprecipitation of Argonaute (AGO), such as HITS-CLIP [11], PAR-CLIP [12], iPAR-CLIP [13]
and CLASH [14]. Since these techniques allow the isolation of the RNA molecules that interact with
all miRNAs, the major disadvantage is that they favor the identification of the targets of the highly
expressed miRNAs. To overcome this limitation, we performed an miRNA pull out assay [15] that is
based on the capture of the specific miRNA/target complexes through the transfection of a biotinylated
version of the miRNA of interest. We already used this technique associated with the microarray
for target identifications [16], and more recently we combined the miRNA pull out assay with NGS
technology to identify the miR-26a-5p targetome in PCa cells [17].
In the present work we isolated and identified the mRNA targets associated with miR-28-5p
(miR-28-5p targetome) in a PCa cell line. We focused on SREBF2, validating miR-28-5p/SREBF2
interaction and demonstrating that SREBF2 inhibition exerts TS activity in PCa cells.
2. Materials and Methods
2.1. Cells and Culture Conditions
DU-145, 22Rv1 and LNCaP cells were grown in RPMI Medium 1640 (EuroClone) whereas PC3
cells were grown in HAM’s Medium (Euroclone, Milan, Italy), V-CaP cells in DMEM (EuroClone)
and HCT116 Dicer-/- cells in McCOY’s (EuroClone). All the media were completed by adding 10%
FBS (Fetal Bovine Serum, EuroClone), 1% penicillin/streptomycin (EuroClone) and 1% L-glutamine
(Sigma-Aldrich). The cells were incubated at 37 ◦C in a humidified atmosphere containing 5% CO2.
2.2. Transfection
Transient transfections of miRNAs mimics (miR-28a-5p), miRNA inhibitor (d-28-5p), SREBF2
inhibitor (siR-SREBF2) or control (CT) (GenePharma, Shanghai, China) in DU-145, LNCaP or HCT116
Dicer−/− cells, were performed using Lipofectamine 2000 (Thermo Fisher, Waltham, MA, USA)
following the manufacturer’s protocol. Briefly, 1.5 × 105 cells were seeded in P30 dishes and transfected
after 48 h using 10 µL of Lipofectamine. The transfected cell suspension was used for cellular and
molecular assays.
2.3. Cell Proliferation
1 × 105 DU-145 or LNCaP cells were seeded in a series of P30 dishes and transfected with either
miR-28-5p mimic/inhibitor, SREBF2 inhibitor, or control. 48 h after transfection, these cells were
collected and counted using the Bürker chamber.
2.4. Survival Assay
To evaluate cell survival, cells were seeded at a cell density of 200 cells/P60 dishes to allow
colony formation. Dishes were stained after 10–12 days with 0.1% Crystal Violet in 20% methanol,
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and the fraction of surviving cells was calculated as the ratio between number of colonies/number of
seeded cells.
2.5. Soft Agar Colony Formation Assay
1 × 105 DU-145 cells were resuspended in culture medium plus 0.3% agarose and plated on an
agarose base (RPMI plus 0.6% agarose, prepared the day before) in a well of a 6-well plate. After
10–15 days, the colonies that were visible in five randomly chosen microscope fields were counted
using a 10× objective.
2.6. Wound Healing Assay
2 × 105 DU-145 cells were seeded in the two chambers of a culture insert (IBIDI, Martinsried,
Germany) previously placed on a P30 dish. The insert was removed at 80% of cell confluence (0 h) in
order to leave the cells free to migrate and to fill the empty space. The cells were observed at 6, 9 and
13 h after the insert removal, with 10× and 20× objectives. The images were taken using a Leica DM IL
light emitting diode (LED) microscope and analyzed with ImageJ. The migratory rate of each sample
was calculated as the relative percentage of gap closure at 13 h versus 0 h.
2.7. Transwell Assay
The 24-well cell culture chamber (Falcon) with 0.4 µm PET membrane covered (invasion assay) or
not (migration assay) with 300 µg/mL Matrigel (BD) was used to measure the migratory or invasive
rate of DU-145 in different conditions. 5 × 104 cells were inoculated onto the upper chamber in a serum
free medium and the medium with serum and growth factor were added in the lower chamber and
incubated for 13 h. The non-invading/migrated cells on the upper surface of the upper chamber were
wiped off with cotton swab, whereas the invading/migrated cells on the lower surface of the upper
chamber were fixed with 2% paraformaldehyde and stained with 0.1% crystal violet dissolved in 20%
methanol and allowed to be dried at room temperature. Lysis was performed with 10% acetic acid
and the optical density (OD 590 nm) of the solution was detected with a ChroMate microplate reader
(Awareness Technology, Westport, CT, USA), and used to measure cell proliferation.
2.8. miRNA Pull Out Assay
The miRNA pull out assay was performed as described in Rizzo et al. [17]. DU-145 was transfected
using Lipofectamine 2000 (Thermo Fisher, Waltham, MA, USA) with 60 nM of either miR-28-5p duplex
(ds-miR-28CT) or a mix of 3′ biotin-tagged miR-28-5p 8tU (nucleotide 8 was a thiouridine) and miR-28-5p
18tU duplexes (ds-miR-28BIO) (Supplementary Figure S1). All oligos were synthetized by Bio-Synthesis
Inc. (Lewisville, TX, USA), and 24 h after transfection, these cells were irradiated with ultraviolet (UV)
(365 nm, 2J/cm2) using the Bio-Link crosslinking (BLX) (Vilmer Lourmat, Marne-la-Vallée, France)
and total RNA extracted with TRIzol (Thermo Fisher, Waltham, MA, USA) directly on adherent cells
following the manufacturer’s protocol (Supplementary Figure S2). 15 µg of RNA was incubated
4 h at 4 ◦C with 100 µL of streptavidin-conjugated beads (Streptavidin Sepharose high performance,
GE Healthcare, Chicago, IL, USA) and the RNA complexed with the beads was recovered using
TRIzol. We performed two biological replicates obtaining two miR-28CT (control) and two miR-28BIO
(miR-28-5p) pull out samples consisting of background RNA and ds-miR-28BIO/interacting mRNA
complexes, respectively.
2.9. Targets Identification by Next Generation Sequencings (NGS)
The RNA obtained after the miRNA pullout procedure (Supplementary Figure S2) from both
miR-28CT (background RNA) and miR-28BIO pull out samples was used for the construction of the
cDNA libraries using the TruSeq Stranded Total RNA Sample Preparation kit (Illumina, San Diego,
CA, USA) according to the manufacturer’s suggestions. cDNA libraries were sequenced using the
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HiSeq2000 (Illumina) in single-reads mode (50bp) obtaining about 20 million reads for each sample
(fastq files).
2.10. NGS Data Analysis
NGS data (GEO accession number GSE143589) were analyzed using the Galaxy platform
(https://usegalaxy.org/), by applying several tools: FASTQC to check the quality of the raw sequence
data, TopHat2 for the alignment of the reads on human genome (hg38) and Cufflinks set of tools
to estimate the abundance of transcripts. Specifically, Cuffdiff was used to perform differential
expression analysis, and we found transcripts enriched in the miR-28BIO in comparison to miR-28CT
pull out samples. We selected the enriched transcripts with q-value < 0.05 (miR-28-5p targetome)
(Supplementary Figure S2).
2.11. Bioinformatics Analyses
The available miRNAs-mRNAs expression data and clinical parameters of patients of MSKCC
Prostate Oncogenome Project [18] were retrieved from cBioPortal (http://www.cbioportal.org/; GEO
accession number: GSE21032). This dataset consists of 99 primary and 14 metastatic tumor tissues and
27 normal controls. Nonparametric tests (i.e., Wilcoxon, Kruskal–Wallis and Spearman rank-correlation)
and recurrence-free survival analysis were conducted in R. In more details, the probabilities of
biochemical recurrence (BCR) events, defined as PSA ≥ 0.2 ng/mL on two occasions, were estimated
with the Kaplan–Meier method (Kaplan–Meier, 1958) and then compared between groups with log-rank
statistics using “survival” R packages.
For the correlation analysis between miR-28-5p expression level and Gleason score/Tumor T stage,
The Cancer Genome Atlas (TCGA) Prostate Adenocarcinoma (PRAD) primary tumors (n = 494) data
were investigated from work by the Broad Institute TCGA Genome Data Analysis Center (2016) [19].
2.12. Bioinformatics Analyses Related to miRNA Pull Out Assay
To identify the miR-28-5p predicted targets in the miR-28-5p targetome, we performed a target
prediction analysis by using the script version of TargetScan 7 [20], PITA [21] and RNA22 [22]
(Supplementary Figure S2). The different algorithms have different settings and filters. For PITA
and RNA22 we applied the filter for a maximum of one mismatch and one G:U in the seed match.
Moreover, for PITA we selected a score (i.e., the ddG score based on the folding energy) ≤ −10. For
RNA22 thresholds for the folding energy ≤ −10 and a p-value ≤ 0.05 were applied. We considered
putative targets if at least one target prediction algorithm was able to detect the interaction. The 3′UTR
sequences of the transcripts belonging to the miR-28-5p targetome were obtained by using UCSC Table
Browser (http://genome.ucsc.edu/).
For the Gene Set Enrichment Analysis, the GSEA online tool (http://software.broadinstitute.org/
gsea/msigdb/index.jsp) was used to discover enriched gene functions (q < 0.05), setting the MSigDB
(the Molecular Signatures Database) as annotated gene lists.
To evaluate the presence of putative miR-28-5p binding sites in the SREBF2 ORF and 5′UTR
we used RNAhybrid [23] considering the binding sites with the MFE (minimum free energy) value
≤ –24 Kcal/mol. We also confirmed the predicted binding site using PITA and RNA22.
2.13. Quantification of miRNAs and mRNAs (qRT-PCR)
Total RNA was extracted from 1× 106 cells using the miRNeasy mini kit (Qiagen, Hilden, Germany)
following the manufacturer’s protocol. 1 µg of total RNA was used for the reverse transcriptase
reaction, performed, according to the manufacturer’s recommendation, using either the QuantiTect
reverse Transcription kit (Qiagen) or the miScript II RT kit (Qiagen) to retrotranscribe mRNAs or
mature miRNAs, respectively. The quantification of mRNAs and mature miRNAs were performed
with Rotor-Gene Q 2plex (Qiagen), using the SsoAdvanced™ SYBR® Green Supermix (BIO-RAD,
Hercules, CA, USA) or the miScript SYBR Green PCR Kit (Qiagen) respectively, according to the
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manufacturer’s protocol. The relative quantification was performed using the Rotor-Gene Q Software,
by normalizing to the internal controls (GAPDH, ACTB and HPRT for mRNAs and U6, SNORD55 and
SNORD110 for mature miRNAs). The miR-28a-5p relative expression level in tumor cell lines was
determined with respect to RNA from normal cells (FirstChoice human total RNA, Ambion, Austin,
TX, USA). All reactions were performed in triplicate, and the results are expressed as the mean of at
least three biological replicates.
2.14. Western Blot Analysis
Proteins were extracted from cell pellets using Lysis Buffer (1 M Tris HCl pH 8, Triton × 100 1%,
Na deoxycholate 0.25%) with the addition of PMSF 1mM. Proteins quantification was performed with
the colorimetric method using the Biorad protein Assay Reagent (BIO-RAD). The ChroMate microplate
reader (Awareness Technology, Westport, CT, USA) was used to measure the absorbance at 595 nm.
To perform Western blot, proteins were separated on polyacrylamide gels SDS-PAGE (10%, gel precast
MINI-PROTEAN® TGX Stain-FreeTM, BIO-RAD), and transferred to 0.2 µm nitrocellulose membranes
by electro blotting using the Trans-Blot Turbo Blotting System (BIO-RAD). The membranes were then
blocked with 5% nonfat dry milk solution in TBST. Anti GAPDH (Cell Signaling) (1:20,000) and anti
SREBF2 (Santa Cruz Biotechnology, Dallas, TX, USA) (1:500) primary antibodies were used to incubate
the membranes overnight at 4 ◦C followed by a 1-h incubation with the recommended secondary
antibody. Bands were revealed using ECL (GE Healthcare, Chicago, IL, USA). Images were detected
and protein quantified using the ChemiDoc system (BIO-RAD).
2.15. Vectors Construction
The sequence of the 3′UTR (ENSG00000198911: 31-1763, pSREBF23’UTR), the 5′UTR and first
part of the ORF (ENSG00000198911: 1753-3611, pSREBF25’UTR-ORFI) and the second part of the ORF
(ENSG00000198911: 3696-5213, pSREBF2ORFII) were cloned downstream of the luciferase coding
sequence into the pmiR vector (pMIR-Report Luciferase, Ambion). The miR-28-5p sensor was built by
cloning two perfect match sequences complementary to miR-28-5p sequence downstream from the
luciferase in the pmiR vector.
2.16. Luciferase Reporter Assay
To investigate the interaction between the miR-28-5p and SREBF2 transcript, 1.5 × 105 HCT116
Dicer−/− colon cancer cells were seeded in each well of a 12-well plate and after 24 h they were
co-transfected with 150 ng of pSREBF23’UTR (or pSREBF25’UTR-ORFI or pSREBF2ORFII), 100 ng of pRL
control vector-TK (Renilla, Promega) and with 60 nM of miR-28-5p mimic (or CT). The transfection
reaction was performed using Lipofectamine 2000 (Thermo Fisher) according to the manufacturer’s
instructions. The luciferase assay was performed one day after transfection, using the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI, USA), according to the manufacturer’s instructions.
The luminometer GloMax-Multi Detection System (Promega,) was used to evaluate the luminescence,
and the pRL-TK (Renilla) was used to normalize the luminescence arising from pmiR-SREBF2 vectors.
2.17. Statistical Analyses
All experimental results are expressed as mean SD of at least three independent experiments.
Data were analyzed with Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001).
3. Results
3.1. miR-28-5p Showed Antitumor Effects in PCa
We previously demonstrated that miR-28-5p is downregulated in the androgen independent PC-3
and DU-145 PCa cell lines, and that its re-expression in DU-145 cells exerts a tumor suppressor activity
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by reducing cell proliferation/survival, increasing apoptosis and inducing an increase of cells in G1
phase [10].
In this paper, we first measured miR-28-5p level in a larger number of PCa cell lines, demonstrating
that this miRNA was generally downregulated in PCa in vitro (Figure 1A). To investigate whether
miR-28-5p re-expression plays a role in PCa cell migration and invasion, we overexpressed miR-28-5p
(Figure 1B) in DU-145 cells and performed both a wound healing assay (Figure 1C) and trans-well assays
(Figure 1D,E). The results showed that miR-28-5p is able to inhibit both the migration (Figure 1C,D) and
the invasion (Figure 1E) ability of DU-145 cells. In line with these results, the expression of the epithelial
marker E-cadherin 1 (CDH1) and the mesenchymal marker vimentin (VIM) increase and decrease,
respectively, after miR-28-5p overexpression (Figure 1F). We also evaluated the anchorage-independent
growth using the soft agar colony formation assay after miR-28-5p re-expression. The number of
anchorage-independent colonies was significantly decreased after miR-28-5p re-expression (Figure 1G).
These data support the tumor suppressor role of miR-28-5p by acting in various aspects of tumor biology.
Figure 1. Effect of miR-28-5p re-expression in PCa cells. (A) Analysis of the miR-28-5p expression level
by qRT-PCR in prostate cancer cell lines with respect to the normal cells RNA. (B) Relative expression
level of miR-28-5p, evaluated by qRT-PCR, after miR-28-5p transfection in DU-145 cells. Cell migration
(C,D) and invasion (E) of DU-145 cells after miR-28-5p overexpression evaluated by wound healing
assay (C) and trans-well assay (D,E). (F) Relative expression of E-cadherin 1 (CDH1) and vimentin
(VIM) in miR-28-5p overexpressing versus normal DU-145 cells. (G) Number of colonies formed in soft
agar in DU-145 cells after miR-28-5p or CT overexpression. * p < 0.05, ** p < 0.01, *** p < 0.001, unpaired
t-test.
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To evaluate the relevance of miR-28-5p in PCa tumorigenesis we first checked the expression of
this miRNA in tumor/normal tissues of PCa patients using the miRNAs expression data deposited in
cBioPortal database. We verified that miR-28-5p tends to be less expressed in primary tumors and
shows a significant downregulation in metastatic tissues (Figure 2A). These results are in line with the
anti-invasive/-migratory ability of miR-28-5p re-expression.
Figure 2. Association of miR-28-5p expression with clinical parameters in PCa patients. (A) Analysis
of miR-28-5p expression level data of the Memorial Sloan Kettering Cancer Center (MSKCC)
study’s patients. The significances according to the Kruskal–Wallis and Wilcoxon test are indicated.
(B) Kaplan–Meier curves for recurrence-free survival events between MSKCC patients after dividing
samples into two groups according to the 25st quartile of miR-28-5p expression level. Log-rank test’s
p-value is shown. The miR-28-5p expression levels (log2RPMK) of TGCA PRAD samples are shown
and grouped by pathological T stage (C) and Gleason score (D) with p-value from the Spearman’s test
of association.
In addition, we found that patients with lower miR-28-5p or LPP expression (the miR-28-5p
host gene, that display an expression pattern resembling the one of miR-28-5p, Supplementary
Figure S3A,B) presented a significantly lower recurrence-free survival (Figure 2B for miR-28-5p and
Supplementary Figure S3C for LPP). Finally, exploiting the primary tumor samples from TCGA Prostate
Adenocarcinoma Study (n = 494), we found that miR-28-5p expression is inversely associated with
both the pathological T stage (Spearman rho = −0.12, p-value = 0.008, Figure 2C) and the Gleason score
(Spearman rho = −0.14, p-value = 0.001, Figure 2D).
Overall data demonstrated that miR-28-5p acts as a TS-miRNA in PCa cells regulating key
pathways involved not only in tumor cell proliferation and survival, but also invasion and migration,
and suggested that this miRNA plays a role in tumor progression in vivo.
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3.2. Identification of miR-28-5p/Targetome
To discover the pathways affected by miR-28-5p regulation we exploited the miRNA pull out
assay [15] adequately revised [17]. This protocol allowed the capture and identification through next
generation sequencing (NGS, RNAseq) of the RNAs interacting with miR-28-5p using a biotinylated
version of miR-28-5p. The transcripts significantly enriched in the captured miR-28-5p transcriptome
(see Material and Methods for more details and Supplementary Figure S2 for a flow chart of the overall
study) were named the miR-28-5p targetome. The miR-28-5p targetome consisted of 191 putative
targets, mostly of which (98%) (187 out of 191) were coding RNAs (Supplementary Table S1). To validate
the reliability of targets identification, we ranked the 191 targets according to the RNAseq fold change
enrichment and we randomly selected and measured the enrichment of eight of them by qRT-PCR.
The results confirmed that all the selected targets were enriched (Figure 3A). We then evaluated the
enrichment of miR-28-5p predicted targets in miR-28-5p targetome using three different miRNA-target
prediction algorithms (TargetScan 7, PITA and RNA22). We found that the 61% (117 out of 191) of the
targets were predicted by at least one algorithm (Figure 3B and Supplementary Table S2) supporting
the validity of the method to identify miRNA targets.
Figure 3. Analysis of miR-28-5p targetome. (A) Evaluation of the enrichment of miR-28-5p selected
targets in the miR-28BIO compared to miR-28CT pull out samples by qRT-PCR. (B) Pie chart representing
the percentage of the predicted/non-predicted targets (upper panel) and the percentage of the targets
predicted by one, two or three algorithms (lower panel) in the miR-28-5p targetome. (C) Results of the
MSigDB gene sets analyses showing the identified genes families. (D) Enrichment of the miR-28-5p
targets belonging to the “transcription factors” family in the miR-28BIO compared to miR-28CT pull out
samples by qRT-PCR. * p < 0.05, ** p < 0.01, *** p < 0.001, unpaired t-test.
We considered only the targets predicted by at least one prediction algorithm. To identify the
pathways and the biological processes to which the selected targets belonged to, we first performed gene
set enrichment analysis using the GSEA online tool, but we did not identify significantly (FDR ≤ 0.01)
enriched pathways. Therefore, we shifted to a different bioinformatics approach, and we evaluated
whether the selected miR-28-5p targets belonged to gene families using the Molecular Signature
database (MSigDB) gene sets used by GSEA, which categorizes genes in gene families with annotated
function. In this way, we discovered that the most enriched gene family was the “transcription factor”
family (Figure 3C) that includes genes such as RNF41, ZNF25, ZNF22 (predicted by TargetScan 7),
SREBF2, ZNF264 (predicted by RNA22) and EZH1 (predicted by Pita, TargetScan 7 and RNA22).
We verified whether the six selected targets were enriched in miR-28-5p targetome by qRT-PCR and
validated the enrichment of four out of six targets (Figure 3D).
Cells 2020, 9, 354 9 of 15
3.3. miR-28-5p Directly Regulated SREBF2 Expression
We focused on the transcription factor SREBF2 as it is a potential oncogenic transcription
factor in prostate cancer [24]. To verify the role of SREBF2 in prostate cancer cells, we silenced
SREBF2 in DU-145 cells and 48 h later we evaluated several cellular readouts. We found that the
SREBF2 inhibition (Figure 4A) reduced cell proliferation (Figure 4B,C), survival (Figure 4D) as well as
migration (Figure 4E,F) and invasion (Figure 4G), measured by both wound healing and trans-well
assays. Even in this case the expression of the epithelial/mesenchymal markers was in accordance
with the migration/invasion data (Figure 4H). On the contrary, SREBF2 silencing did not affect the
anchorage-independent growth (Figure 4I). These results suggest that the inhibition of SREBF2 was
able to affect the majority of the tumor processes affected by miR-28-5p re-expression.
Figure 4. Evaluation of the SREBF2 role in DU-145 PCa cells. (A) SREBF2 inhibition by siR-SREBF2
transfection in DU-145 cells analyzed by qRT-PCR and western blot analysis. Evaluation of SREBF2
silencing effect on proliferation (B), survival (D) migration (E,F) and invasion (G) in DU-145 cells.
Relative expression of proliferation (Ki-67, c-MYC and cyclin D1 (CCND1)) (C), epithelial (E-cadherin 1
(CDH1)) and mesenchymal markers (Vimentin (VIM)) (H) in miR-28-5p overexpressing versus normal
DU-145 cells. (I) Number of colonies formed in soft agar in DU-145 cells after miR-28-5p overexpression
or SREBF2 silencing. * p < 0.05, ** p < 0.01, *** p < 0.001, unpaired t-test. ns, not significant.
We then verified whether miR-28-5p regulated SREBF2. We transfected miR-28-5p in DU-145
cells and found that miR-28-5p overexpression determined a slight but significant decrease of SREBF2
expression both at the mRNA and protein levels (Figure 5A). The same results were obtained with
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the androgen-dependent PCa cell line LNCaP in which miR-28-5p overexpression, and SREBF2
inhibition determined a decrease of cells proliferation (Supplementary Figure S4A–C) and miR-28-5p
negatively-regulated SREBF2 expression (Supplementary Figure S4D). To validate miR-28-5p interaction
with SREBF2, we performed the luciferase reporter assay using a reporter vector encompassing SREBF2
3′UTR, and unexpectedly, we discovered that miR-28-5p did not regulate SREBF2 by interacting
with the 3′UTR (Figure 5B). As it has already been demonstrated that miRNAs can regulate gene
expression also by interacting with the ORF [25] or the 5′UTR [26] of their targets, we used RNAhybrid
to verify whether the SREBF2 5′UTR-ORF contained putative miR-28-5p recognition sites, and we
found three putative sites of interaction in the CDS region (Supplementary Table S3). It is of note that
the majority of the binding sites were predicted also by RNA22 and PITA (Supplementary Table S3). We
produced two luciferase reporter vectors, one encompassing the 5′UTR plus the first part of the ORF
(pSREBF25’UTR-ORFI, that includes one putative recognition site), and the other encompassing the second
part of the ORF (pSREBF2ORFII, that includes two putative recognition sites) (Supplementary Table S3).
We performed a luciferase reporter assay and found a significant reduction of luciferase activity after
miR-28-5p overexpression only with pSREBF25’UTR-ORFI (Figure 5C,D). Overall, these data suggested
that miR-28-5p repressed SREBF2 expression by interacting with the SREBF2 CDS region.
Figure 5. Analysis of miR-28-5p/SREBF2 interaction in PCa cells. (A) Quantification of SREBF2 mRNA
and protein level in miR-28-5p versus CT transfected DU-145 cells. Relative luciferase activity after
the cotransfection of pSREBF23′UTR (B), pSREBF25’UTR-ORFI (C), pSREBF2ORFII (D) and either CT or
miR-28-5p. (E) Relative luciferase mRNA level, analyzed with qRT-PCR, in DU-145 cotransfected with
miR-28-5p sensor and miR-28-5p mimic or inhibitor versus miR-28-5p sensor/CT cotransfected cells.
(F) Relative luciferase mRNA level, analyzed by qRT-PCR, in DU-145 cotransfected with miR-28-5p
sensor/siR-SREBF2 versus miR-28-5p sensor/CT cotransfected cells. * p < 0.05, ** p < 0.01, *** p < 0.001,
unpaired t-test. ns, not significant.
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Finally, to evaluate whether the SREBF2/miR-28-5p interaction may also affect the availability of
free miR-28-5p, we considered the possibility that SREBF2 might function as a sponge for miR-28-5p.
For this purpose, we built a miR-28-5p sensor (miR28sens), consisting of a luciferase reporter vector in
which two miR-28-5p perfect match sequences were cloned downstream of the luciferase gene. We
first verified the capability of this sensor to detect miR-28-5p variations by co-transfecting the sensor
with a miR-28-5p mimic or inhibitor, and then evaluating the luciferase mRNA variation by qRT-PCR:
as expected the luciferase mRNA levels decreases or increases when the miR-28-5p was overexpressed
or inhibited, respectively (Figure 5D). Then we tested SREBF2 sponge activity by co-transfecting
the sensor with a SREBF2 inhibitor or control, but we did not detect any significant variation of the
luciferase mRNA, suggesting that SREBF2 did not act as a sponge of miR-28-5p.
4. Discussion
Although in some tumor types an increased expression level of miR-28-5p has been reported [27–29],
most of the papers regarding the role of this miRNA in cancer suggested a prevalent TS activity. We
already demonstrated that miR-28-5p is involved in both tumor cell proliferation and survival by
inhibiting cell proliferation and colony forming ability, and by inducing apoptosis and increasing the
percentage of DU-145 cells in G1 phase [10]. In this paper we also evaluated whether this miRNA
also plays a role in the capability of the tumor cells to migrate and invade, finding that miR-28-5p
re-expression determined a reduction of the PCa cells capability to grow unattached to a matrix and
also to migrate and invade. These results were in line with the fact that miR-28-5p expression tends to
decrease in tumor tissues and is more severely diminished in metastatic tissues. These data indicated
that miR-28-5p exerts its TS activity by affecting almost all the aspects of tumor biology, including the
cellular processes fundamental for tumor development and progression, although this is not true for
all cancer types [6]. In addition, we discovered that miR-28-5p expression was also associated with
two fundamental clinicopathological characteristics of prostate cancer progression (pathological T
stage and the Gleason score), as well as with biochemical relapse. These data reinforce the TS activity
of miR-28-5p in PCa and, as already demonstrated in gastric and colorectal cancer [6,30], suggesting
a possible role of this miRNA as a prognostic biomarker. Another point is that we demonstrated
in vitro that miR-28-5p re-expression could reduce processes linked to tumor growth. In line with our
observations are the data obtained by Bartolomé-Izquierdo et al. [31] which demonstrated that the
miR-28-5p re-expression blocked tumor growth in a Burkitt lymphoma murine model, opening the
way to a possible therapeutic use of miR-28-5p (replacement therapy). All these aspects justified the
interest to identify the miR-28-5p targetome in PCa.
The exploitation of the miRNA pull-out assay technique optimized with NGS technology allowed
us to identify the miR-28-5p targetome in PCa that consists of 191 targets. Considering the miR-26a-5p
targetome of DU-145 cells obtained in our previous work [17] we observed that miR-28-5p exerts its TS
activity by interacting with a relative lower number of targets respect to miR-26a-5p (1423 targets). The
fact that miR-28-5p re-expression regulates fewer genes than miR-26a-5p was suggested also by the
proteome analysis, performed using mass spectrometry, after miRNAs re-expression (preliminary data).
The reliability of the method in capturing miR-28-5p targets was demonstrated by the fact that
61% (117 targets) of miR-28-5p targets presented at least one predicted binding site for miR-28-5p.
This evaluation was done using three different prediction algorithms that consider canonical and
non-canonical miRNA/target interactions within the 3′UTR of the targets. We focused on targets with
at least one miR-28-5p predicted binding site and, to catch the targets whose function could be relevant
for miR-28-5p activity, we tested whether some pathways or biological processes were enriched by
the targets. Unfortunately, the analysis did not show pathways significantly enriched by miR-28-5p
targets possibly due to the low number of targets available for the analysis. However, we found that
that some targets belonged to gene families with annotated functions, and in particular, the largest
family was the “transcription factor family”. Given that a transcription factor regulates in turn several
genes, we focused on this family, and in particular on SREBF2 (sterol regulatory element-binding
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protein 2), an essential regulator of genes associated with cholesterol biosynthesis [32]. Aberrant
SREBF2 expression and activity has been associated with PCa progression [24,33,34], probably due to
the increasing need of proliferating cells for the key component of cell membranes such as cholesterol
and other lipids. Indeed, SREBP metabolic pathway impairment is under evaluation as an effective
anti-tumor therapy [35]. In accordance with these observations we demonstrated that the inhibition of
SREBF2 in DU-145 cells induced an anti-tumor activity also in this case by affecting various tumor
characteristics such as cell proliferation, survival and to a lesser extent, invasion and migration. It
is of note that SREBF2 inhibition did not affect the anchorage-dependent growth of DU-145 cells.
Since the silencing of SREBF2 was not able to recapitulate all the effects of miR-28-5p re-expression,
these results suggested that SREBF2 is not the only mediators of miR-28-5p TS activity. In addition,
Chen et al. demonstrated that the reactivation of the MAPK pathway determined an up-regulation of
SREBP proteins promoting metastatic PCa [34]. Given that MAPK1 has been shown to be a miR-28-5p
target in myeloproliferative neoplasm [36], it is possible that miR-28-5p regulates SREBF2 both directly
and indirectly through MAPK. It is of note that MAPK1 is included in the miR-28-5p targetome
(Supplementary Tables S1 and S2).
Finally, during the validation experiments we demonstrated that miR-28-5p re-expression
determines a slight but significative reduction of SREBF2 expression at both the protein and mRNA
levels, and that miR-28-5p regulates SREBF2 expression through the interaction with SREBF2 ORF.
Although miRNAs binding of the ORFs are generally considered less effective [37,38], there are
several lines of evidence that confirmed that sites in both 5′UTRs and ORFs can mediate target
repression [25,39–41]. Moreover, the fact that Helwak et al. [14] using the CLASH technique on HEK293
cells found the interaction between miR-28-5p and the first part of the ORF of SREBF2 further reinforces
our findings.
In conclusion, we demonstrated that miR-28-5p had a TS activity on PCa cells by affecting several
fundamental processes of tumor development and progression. We showed that the miRNA pull-out
assay represents a valid tool to isolate the targetome of a specific miRNA. We demonstrated that SREBF2
is one of the mediators of the miR-28-5p TS activity, given that its inhibition determined a decrease
of tumor cell survival and proliferation and to a lesser extent invasion and migration. Our findings
reinforce the concept that the identification of the targetome of a specific miRNA with anti-tumor
activity allows the identification of new genes or pathways with a role in cancer development and
hence possible therapeutic targets.
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representation of overall study consisting in the miR-28-5p targets capture (through miRNA pull-out assay) and
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